Organogenesis Holdings Inc.

As of June 30, 2026, Organogenesis Holdings, Inc. Class A carries a market capitalization of 270.22M, placing it among publicly traded companies globally. Its enterprise value stands at 410.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Organogenesis Holdings, Inc. Class A's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Organogenesis Holdings, Inc. Class A has 128.67M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.67, and the price-to-book ratio stands at 2.08.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 410.89M versus a market cap of 270.22M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Organogenesis Holdings, Inc. Class A maintains a current ratio of 3.52, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Organogenesis Holdings, Inc. Class A posted a negative return on equity (ROE) of -50.02, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.40, reflecting losses generated across the asset base. The company generates approximately 463,914.61 in revenue per employee across its workforce of 857.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.35 indicates how many times Organogenesis Holdings, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Organogenesis Holdings, Inc. Class A recorded 43.23M in income tax expense. The company reported a pretax loss of -30.43M and -73.66M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Organogenesis Holdings, Inc. Class A's stock has declined approximately 74.14% over the past 52 weeks. The 50-day moving average sits at 1.28, while the 200-day moving average is 2.11.

Over the twelve months ended June 30, 2026, Organogenesis Holdings, Inc. Class A generated 397.92M in revenue and converted that into -73.66M in net income, yielding earnings per share of -0.57. EBITDA reached -2.55M, while operating income came in at -29.93M.

As of June 30, 2026, Organogenesis Holdings, Inc. Class A holds 40.35M in cash and equivalents against 58.60M in total debt, resulting in a net debt position of -40.35M. Total book value stands at 129.78M, with working capital of 125.46M providing operational flexibility.

Organogenesis Holdings, Inc. Class A produced 27.99M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.74M in capital expenditures, free cash flow totaled 18.24M - equivalent to 0.14 per share.

Over the twelve months ended June 30, 2026, Organogenesis Holdings, Inc. Class A posted a gross margin of 70.17, reflecting its pricing power and cost economics. The operating margin of -7.52 and net profit margin of -18.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 11.81 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.69, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 15.46, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Organogenesis Holdings, Inc. Class A shareholders.

As of June 30, 2026, Organogenesis Holdings, Inc. Class A has an Altman Z-Score of 2.37, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.